We therefore investigated the levels of FACT proteins and the reported targets of curaxin in CML before assessing the ability of the curaxin CBL0137 to extinguish CML primitive cells. This evidence concerns the gene SUPT16H and chronic myelogenous leukemia, BCR-ABL1 positive.